1-20 of 384 Search Results for

statin

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Book Chapter
Series: Contributions to Nephrology
Volume: 178
Published: 30 May 2012
10.1159/000337829
EISBN: 978-3-318-02163-9
... as an emerging cardiovascular risk factor. PD patients exhibit a more overtly abnormal lipid profile than HD patients, probably due to the metabolic interference of the peritoneal dialysis fluid. Statins are the main drugs for the treatment of dyslipidemia and they are able to decrease all LDL subclasses levels...
Book Chapter
Series: Contributions to Nephrology
Volume: 178
Published: 30 May 2012
10.1159/000337828
EISBN: 978-3-318-02163-9
... understood, but both the protein loss in the dialysate, and the glucose absorption from the dialysate may contribute to these alterations. Hydroxymethylglutaryl coenzyme A reductase inhibitors, more commonly known as statins, are effective to reduce low density cholesterol levels in PD patients and have few...
Book Chapter
Series: Contributions to Nephrology
Volume: 163
Published: 15 June 2009
10.1159/000223797
EISBN: 978-3-8055-9203-1
... and the glucose absorption from the dialysate may contributes to these alterations. Hydroxymethylglutaryl coenzyme A reductase inhibitors, more commonly known as statins, are effective to reduce low density cholesterol levels in PD patients, but so far no large studies has been performed concerning the effects...
Book Chapter
Series: Advances in Cardiology
Volume: 44
Published: 03 November 2006
10.1159/000096750
EISBN: 978-3-318-01395-5
... of the same properties in terms of activation of pro-inflammatory,pro-oxidant and pro-atherosclerosis pathways. Statins in particular have been shownto influence the biology of endothelial cells, vascular smooth muscle cells and constituentsof the interstitial matrix, particularly fibroblasts. It is no wonder...
Book Chapter
Series: Advances in Cardiology
Volume: 45
Published: 14 February 2008
10.1159/000115192
EISBN: 978-3-8055-8428-9
... Abstract Evidence of the effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductaseinhibitors (statins) within continuum of atherothrombotic conditions and particularly in the treatmentand prevention of coronary heart disease (CHD) is well established. Large-scale, randomized,prospective...
Book Chapter
Book Chapter
Series: Contributions to Nephrology
Volume: 178
Published: 30 May 2012
10.1159/000337821
EISBN: 978-3-318-02163-9
... rates of LDL. The reviews some of the biochemistry of lipids in uremia and discusses the randomized trial data that support these statements and provides greater detail regarding use of statin in patients with stages 4 and 5 CKD. Caution should be used in dosing statins in stage 3b or higher CKD...
Book Chapter
Series: World Review of Nutrition and Dietetics
Volume: 100
Published: 12 August 2009
10.1159/000235713
EISBN: 978-3-8055-9225-3
... of cholesterol by skeletal muscle after exercise, the impact of dietary cholesterol, and the fate of cholesterol (membrane, steroids, etc.) remain to be determined. Model of skeletal muscle hypertrophy with proposed effects of statins, cholesterol and lipid rafts. © = Influence of cholesterol; ş = influence...
Book Chapter
Series: World Review of Nutrition and Dietetics
Volume: 100
Published: 12 August 2009
EISBN: 978-3-8055-9225-3
... muscle actions. J Sports Med Phys Fit 2004;44:193-199 8. Riechman SE, Kean D, Andrews RD, Gasier H, Hammer S: Dietary cholesterol alters recovery from eccentric muscle damage in humans. Med Sci Sports Exerc 2006;38:S368 9. Riechman SE, Andrews R, MacLean DA: Statins and dietary and blood...
Book Chapter
Series: Nestlé Nutrition Institute Workshop Series
Volume: 82
Published: 02 November 2015
EISBN: 978-3-318-05499-6
... 2012;2:58-67. 17. Dixon JB, Zimmet P, Alberti KG, Rubino F: Bariatric surgery: an IDF statement for obese type 2 diabetes. Arq Bras Endocrinol Metabol 2011;55:367-382. 18. Ginsberg HN: Review: efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin...
Book Chapter
Series: Nestlé Nutrition Institute Workshop Series
Volume: 82
Published: 02 November 2015
10.1159/000382003
EISBN: 978-3-318-05499-6
.... However, there is little additional benefit regarding weight loss and its cost should be considered against a program of eating and behavioral modification. Dyslipidemia and the Metabolic Syndrome Statins Statins reduce plasma LDL-c levels and have moderate effects on TG and HDL-c levels...
Book Chapter
Series: Contributions to Nephrology
Volume: 178
Published: 30 May 2012
EISBN: 978-3-318-02163-9
...References References 1. Prichard SS: Management of hyperlipidemia in patients on peritoneal dialysis: current approaches. Kidney Int 2006;(suppl 103)S115-S117 2. Epstein M, Vaziri ND: Statins in the management of dyslipidemia associated with chronic kidney disease. Nat Rev Nephrol 2012...
Book Chapter
Series: World Review of Nutrition and Dietetics
Volume: 100
Published: 12 August 2009
10.1159/000235714
EISBN: 978-3-8055-9225-3
... termination of JUPITER, a trial testing rosuvastatin, presumably the most effective statin in terms of cholesterol lowering, against a placebo in the primary prevention of CHD [ 13 , 14 ]. With this announcement, investigators probably wanted to communicate that rosuvastatin, contrary to ezetimibe...
Book Chapter
Series: World Review of Nutrition and Dietetics
Volume: 102
Published: 08 August 2011
10.1159/000327834
EISBN: 978-3-8055-9780-7
... the recommendations. Indeed, the ‘Guidelines for the Diagnosis and Prevention of Atherosclerotic Disease - 2007’, issued by the Japan Atherosclerotic Society and ten related medical societies, included this concept citing more than 500 medical papers worldwide. The reported effectiveness of statins, cholesterol...
Book Chapter
Series: World Review of Nutrition and Dietetics
Volume: 113
Published: 17 April 2015
EISBN: 978-3-318-02691-7
..., Verschuren WM, Klungel OH: Dose-dependent cholesterol-lowering effects of phytosterol/phytostanol-enriched margarine in statin users and statin non-users under free-living conditions. Public Health Nutr 2011;14:1823-1832. 6. Malhotra A, Shafiq N, Arora A, Singh M, Kumar R, Malhotra S: Dietary...
Book Chapter
Series: Contributions to Nephrology
Volume: 199
Published: 17 December 2021
10.1159/000517704
EISBN: 978-3-318-06937-2
.... Treatment: For “CKD and CHD” we discuss the association of CKD and CHD in community-based populations, traditional risk factor in CKD, non-traditional risk factor in CKD, reduced risk of CHD in patients with CKD, statin treatment, hypertension treatment, anti-platelet aggregation therapy, treatment of CHD...
Book Chapter
Series: Contributions to Nephrology
Volume: 149
Published: 10 May 2005
10.1159/000085647
EISBN: 978-3-318-01222-4
... demonstrating the benefit of common interventions, such as statin treatment for dyslipidemia,improvement of HbA1c levels in diabetic patients, implementation of physical exercise,normalization of Hgb and achievement of adequate dry weight in dialysis patients. Thisarticle gives an overview of modifiable...
Book Chapter
Series: World Review of Nutrition and Dietetics
Volume: 100
Published: 12 August 2009
EISBN: 978-3-8055-9225-3
... of statin pleiotropic effects: hypotheses versus evidence. Circulation 2005;111:2280-2281 32. Nissen JE: Courage under fire: what is the optimal approach to initial treatment of stable angina?. Curr Cardiol Rep 2008;10:79-80 33. Nissen SE, Tuzcu EM, Schoenhagen P, et al: Effect of intensive compared...
Book Chapter
Series: Advances in Cardiology
Volume: 44
Published: 03 November 2006
10.1159/000096747
EISBN: 978-3-318-01395-5
... contribute to the increased risk of cardiovascular diseaseassociated with hypercholesterolaemia and their assessment may improve risk stratification.Lipid-lowering therapy, particularly with statins, generally leads to a reduction inarterial stiffness, re-enforcing the concept that stiffness is a modifiable...
Book Chapter
Series: Endocrine Development
Volume: 30
Published: 10 December 2015
10.1159/000439334
EISBN: 978-3-318-05637-2
... parathyroid hormone injections, soluble FGFR3 therapy, and meclozine and statin treatments. Among the putative targets to antagonize FGFR3 signaling, CNP (or BMN111) is one of the most promising strategies. BMN111 acts as a key regulator of longitudinal bone growth by downregulating the mitogen-activated...